Appen delivers full-year result broadly in line with guidance.

Published 28-FEB-2017 15:24 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Leading global provider of high-quality language data and services to major technology companies and government agencies, Appen (ASX: APX) has delivered a full-year profit of $10.6 million from revenues of $111 million for the 12 months to December 31, 2016.

This was only slightly shy of Bell Potter’s profit forecast of $10.9 million, and given that management has guided to EBITDA growth in the order of mid to high teens in fiscal 2017 the focus is likely to be more on the coming 12 months.

It should be noted here that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Having only listed on the ASX in 2015, Appen has made substantial inroads in a short period of time, having forged relationships with global technology giants and consistently under promised and outperformed.

Appen’s customers include eight of the top 10 global technology companies, including the most prominent social media players.

The company’s consistent outperformance has been reflected in its share price which increased from 56 cents on the day it listed to an all-time high of $3.62 in August 2016, representing a gain of 550%.

Appen has traded in a relatively tight range between $2.75 and $3.00 in 2017, and it is difficult to see this result triggering any sharp share price variation, unless investors were factoring in another period of outperformance.

Headline growth numbers were impressive with underlying revenue, EBITDA and net profit up by 33%, 22% and 23% respectively. Importantly, revenue growth was in part organic, but there were also contributions from new clients.

The only flaw in the result was a slight contraction in margins due to the impact of volume discounts on its Content Relevance business.

Summing up the result, Appen’s chairman, Chris Vonwiller said, “This is another outstanding result for Appen as we have built on last year’s strong performance by focusing on our customers and delivering quality work which has led to revenue growth from new projects and existing programs”.

In discussing industry conditions, Chief Executive, Mark Brayan noted the increasing use of machine learning and artificial intelligence as key drivers of demand for quality data, effectively providing new opportunities for Appen going forward.

Natural language processing, machine learning and artificial intelligence is being increasingly harnessed to automate business processes and personal tasks. These align with Appen’s core product offerings.

The group is debt free with a strong balance sheet and ample cash reserves, leaving it well-positioned to fund internal growth and/or make acquisitions.

Year-to-date revenue plus orders in hand currently total $70 million, more than 60% of last year’s full-year revenues. Management’s full-year EBITDA growth guidance implies a mid-range of $20.1 million, broadly in line with Bell Potter’s fiscal 2017 forecast of $20.7 million.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free